Bpi-2358-103- Randomized Phase 3 Assessment Of Second Line Treatment With Docetaxel + Plinabulin Compared To Docetaxel Alone In Patients With Advanced Non-Small Cell Lung Cancer With At Least 1 Large Lung Lesion
Posted Date: Jun 17, 2019
- Investigator: John Morris
- Specialties: Cancer, Lung Cancer, Oncology
- Type of Study: Drug
The goal of this study is to compare the overall survival of NSCLC patients receiving 2nd-or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease.
To Be Eligible: Must Have Nsclc, Age 18 Or Older, Lesion >10Mm, Life Expetancy >12 Weeks.
Lung Cancer, Nsclc, Phase Iii
For More Information:
Uc Cancer Institute